10-Q: Align Tech Q3 Net Income Halves Amid Restructuring, Lower ASPs

Align Technology reported a 51% drop in third-quarter net income to $56.8 million, driven by significant restructuring charges and declining average selling prices for its clear aligners.

Summary

• Net revenues for Q3 2025 increased by 1.8% year-over-year to $995.7 million.
• Net income for Q3 2025 decreased by 51.0% year-over-year to $56.8 million.
• Diluted EPS for Q3 2025 was $0.78, down 49.7% from $1.55 in Q3 2024.
• Gross profit for Q3 2025 decreased by 6.3% to $639.2 million, with gross margin falling to 64.2% from 69.7% in Q3 2024.
• Operating income for Q3 2025 plummeted by 40.7% to $96.3 million, resulting in an operating margin of 9.7%.
• The company initiated a 2025 restructuring plan in Q3, anticipating $40.0 million to $50.0 million in total expenses, primarily for involuntary termination benefits.
• Restructuring and other charges of $31.8 million were recorded in Q3 2025.
• An impairment loss of $14.9 million on inventory was recognized in Q3 2025, impacting Cost of net revenues.
• An impairment loss of $23.1 million on assets held for sale (Juarez, Mexico manufacturing facility) was recorded in Q3 2025.
• Clear Aligner segment revenues increased by 2.4% to $805.8 million in Q3 2025, driven by a 4.9% increase in case volume, but offset by a 2.4% decrease in average selling price (ASP).
• Systems and Services segment revenues decreased by 0.6% to $189.9 million in Q3 2025, primarily due to lower scanner system sales.
• The effective tax rate for Q3 2025 increased to 40.1% from 30.1% in Q3 2024.
• Cash and cash equivalents stood at $1,004.6 million as of September 30, 2025.
• The company repurchased 523,203 shares for $71.6 million under the April 2025 Repurchase Program in Q3 2025, with $928.4 million remaining.

Sentiment

Score: 3

Explanation: The company reported a significant decline in net income and EPS, coupled with lower gross and operating margins, driven by substantial restructuring charges and asset impairments. While revenue saw a slight increase and case volumes grew, average selling prices declined, and cash from operations decreased. The ongoing macroeconomic headwinds and competitive pressures, alongside numerous legal challenges, paint a challenging picture despite some positive operational metrics.

Positives

• Net revenues increased by 1.8% year-over-year in Q3 2025.
• Clear Aligner case volume increased by 4.9% year-over-year in Q3 2025.
• Clear Aligner case volume for teens and growing patients increased by 8.3% year-over-year in Q3 2025.
• The total utilization rate increased to 7.3 cases per doctor in Q3 2025 from 7.1 cases per doctor in Q3 2024.
• The U.S. dollar weakened against major currencies in Q3 2025, positively impacting financial results.
• Net gain of $3.3 million from foreign currency forward contracts in Q3 2025, compared to a net loss of $24.5 million in Q3 2024.
• Selling, general and administrative expenses decreased by $16.3 million in Q3 2025 compared to Q3 2024, primarily due to lower employee costs and marketing expense.
• The company had no outstanding borrowings under its $300 million revolving credit facility as of September 30, 2025, and was in compliance with all terms.
• HMRC refunded approximately $100 million in VAT assessments, and a Tax Tribunal ruled in Align's favor regarding VAT exemption for clear aligners.

Negatives

• Net income for Q3 2025 decreased by 51.0% year-over-year to $56.8 million.
• Diluted EPS for Q3 2025 decreased by 49.7% year-over-year to $0.78.
• Gross profit decreased by 6.3% in Q3 2025, and gross margin declined to 64.2% from 69.7%.
• Income from operations decreased by 40.7% in Q3 2025, with operating margin falling to 9.7% from 16.6%.
• Cost of net revenues increased significantly by 20.4% in Q3 2025, primarily due to restructuring charges, impairment losses on assets held for sale, and depreciation on assets disposed of.
• Clear Aligner average selling price (ASP) decreased by 2.4% in Q3 2025 due to product mix shift to lower-priced countries/products and higher discounts.
• Systems and Services net revenues decreased by 0.6% in Q3 2025, mainly due to lower scanner system sales.
• An impairment loss on inventory of $14.9 million was recognized in Q3 2025.
• An impairment loss on assets held for sale of $23.1 million was recognized in Q3 2025 related to a manufacturing facility in Juarez, Mexico.
• The effective tax rate increased to 40.1% in Q3 2025 from 30.1% in Q3 2024.
• Net cash provided by operating activities for the nine months ended September 30, 2025, decreased by 18.1% to $370.0 million compared to the same period in 2024.
• Net cash used in financing activities for the nine months ended September 30, 2025, significantly increased to $367.2 million from $152.7 million in the same period in 2024, primarily due to higher share repurchases.
• Orthodontic starts have been down for four consecutive years, and there is a belief that this has led to an increase in orthodontic starts using wires and brackets instead of clear aligners.
• The company initiated a 2025 restructuring plan in Q3 2025, anticipating $40.0 million to $50.0 million in total expenses.

Risks

• Macroeconomic conditions, including inflation, higher interest rates, and global tariff volatility, continue to impede dental patient demand and may lead to a shift to less costly orthodontic treatments like wires and brackets.
• Geopolitical conflicts (e.g., Ukraine, Middle East, China/Taiwan/South China Sea) add market uncertainties, dampen consumer sentiment, and could disrupt operations, supply chains, and sales, particularly impacting the iTero business headquartered in Israel.
• Government shutdowns or reductions in government personnel (e.g., FDA) may impede the ability to obtain and maintain necessary clearances or approvals for products.
• Increasing competition from existing competitors and emerging companies introducing new technologies, lower-priced products, or incorporating AI and machine learning, could lead to commoditization of products or render Align's technology obsolete.
• Dependence on sales of the Invisalign System and iTero intraoral scanners means declines in volume or average selling price (ASP) due to product mix shifts, promotions, or competitive pressures could adversely affect financial results.
• The company is highly dependent on third-party suppliers, some of whom are sole source, for key machines, components, and materials, exposing it to supply chain vulnerabilities and potential disruptions.
• Operational risks include excess or constrained manufacturing capacity, labor shortages, shipping delays, and reliance on sophisticated IT systems, which if disrupted by cybersecurity attacks, software defects, or system outages, could harm operations and reputation.
• The company is subject to antitrust and competition regulations, litigation, and enforcement actions that could result in fines, penalties, or restrictions on business practices.
• Security breaches, data breaches, cybersecurity attacks, or failure to comply with evolving privacy, security, and data protection laws (e.g., HIPAA, CCPA, GDPR, EU AI Act) could lead to liability, reputational harm, and operational disruptions.
• Potential liability for the quality and safety of products and services, as well as how they are advertised and marketed, could result in substantial expenses or damages.
• Increasing sustainability and social (ESG) laws and scrutiny may increase costs, expose the company to liability, and adversely impact reputation and business relationships.
• Implementation of AI and machine learning technologies carries legal and regulatory risks, potential for flawed algorithms or biased data, and could lead to loss of intellectual property or liability for infringement.
• Failure to successfully obtain or enforce intellectual property rights (patents, copyrights, trademarks, trade secrets) could harm the competitive position, especially with reverse engineering by competitors in regions with weaker enforcement.
• Goodwill, finite-lived intangible, or long-lived assets may become impaired, requiring material charges to income based on management's significant judgment in valuation.
• The effective tax rate may vary significantly due to changes in global economic environment, legal entity structure, tax laws (e.g., OECD Pillar Two), and audit settlements.
• The market price for common stock has historically been volatile and is subject to various factors, including operating results, market speculation, competition, and general economic conditions.

Future Outlook

The company anticipates continued macroeconomic challenges, including global tariff volatility, inflation, and higher interest rates, which are expected to impede dental patient demand and potentially lead to a shift towards traditional orthodontic treatments. Geopolitical conflicts are also expected to add market uncertainties. A 2025 restructuring plan is underway, with $40.0 million to $50.0 million in expenses anticipated, aimed at realigning business groups and reducing the global workforce. Capital expenditures for fiscal year 2025 are projected to be approximately $100 million, primarily for manufacturing capacity and treatment planning. The company expects to repurchase an additional $128.4 million of common stock under its April 2025 Repurchase Program through January 2026.

Management Comments

• Our strategic priorities focus on four principal pillars for growth: (i) international expansion; (ii) general dental practitioners (GP) treatment; (iii) patient demand; and (iv) orthodontic utilization.
• Our growth strategy depends on our ability to facilitate the digital transformation of dentistry, our continuous focus on innovation, and expansion to meet and exceed evolving customer expectations as the array of products and services available to them increases.
• We believe that since the second quarter of 2025, sales of our products have been adversely impacted by certain macroeconomic conditions, including global tariff volatility, inflation, and higher interest rates, which we believe have and may continue to impede dental patient demand.
• We believe uncertainty not only impacts consumer purchasing decisions but also the decisions and recommendations that doctors make, especially doctors who offer both clear aligners and wires and brackets in their practices and have the additional time to treat patients with wires and brackets when orthodontic starts are slowing or diminishing.
• We continue to closely monitor the foregoing issues, assess their potential impact on our operations and financial results, and implement plans to seek to mitigate the impact of any adverse events.
• We strive to manage the challenges presented by the foregoing trends and uncertainties, including the macroeconomic conditions, tariffs and retaliatory measures, military conflicts and the evolution of our target markets, by focusing on improving our operations, further increasing flexibility and efficiencies in our processes, adjusting our business models to changing circumstances and offering products that meet market demand.
• Specifically, we are managing financial impacts by implementing strategic product innovations, introductions and pricing actions, implementing cost saving measures, and evaluating hiring needs.
• We believe that our current cash balances and the borrowing capacity under our credit facility, if necessary, will be sufficient to fund our business for at least the next 12 months.

Industry Context

The dental industry is undergoing a rapid digital transformation, with Align Technology positioned as a key facilitator through its Invisalign system and iTero intraoral scanners. However, the market faces significant headwinds from macroeconomic conditions, including inflation and higher interest rates, which are dampening consumer discretionary spending on dental services. This has led to a notable trend of declining orthodontic starts for four consecutive years and a perceived shift towards traditional, less costly wire and bracket treatments, particularly among doctors who offer both options. Competition is intensifying from traditional medical device companies, new market entrants, direct-to-consumer clear aligner providers, and even DSOs manufacturing their own aligners, with a growing focus on incorporating AI and machine learning into new solutions. The industry is also grappling with evolving regulatory landscapes, particularly concerning AI and sustainability, which could impose significant compliance costs and operational changes.

Comparison to Industry Standards

• The filing highlights a general industry trend of orthodontic starts being down for four consecutive years, suggesting a broader market challenge rather than a company-specific issue, though Align's clear aligner revenue per case shipment also decreased.
• The company notes that patient traffic growth has been uneven for many doctors, indicating a widespread impact of macroeconomic conditions on dental practices.
• Align's observation of an increase in orthodontic starts using wires and brackets in lieu of clear aligners suggests a competitive shift within the broader orthodontic market, where traditional methods are gaining ground against digital solutions in a challenging economic environment.
• The company mentions that competitors are incorporating artificial intelligence (AI) and machine learning into new or existing services and technologies, indicating that Align is operating in an industry where technological innovation, particularly in AI, is a key competitive battleground.

Legal Proceedings

• Antitrust Class Actions: Direct purchasers' lawsuit (Simon and Simon, PC) where Align was granted summary judgment, but plaintiffs have appealed to the Ninth Circuit. Oral argument was held on April 10, 2025, and the outcome is currently unpredictable.
• Antitrust Class Actions: Indirect purchasers' lawsuit (Misty Snow) where Align was granted summary judgment on Section 2 allegations, but plaintiffs have appealed to the Ninth Circuit. Oral argument was held on April 10, 2025, and the outcome is currently unpredictable.
• Antitrust Class Actions: Section 1 claims settlement where Align reached a revised settlement of $31.75 million, which received preliminary court approval on May 28, 2025. The full settlement amount was issued to an escrow agency in Q3 2025, and a Final Approval/Fairness hearing is set for November 20, 2025.
• Straumann Litigation: Align filed a lawsuit on April 11, 2024 (amended August 29, 2025) alleging false advertising, unfair competition, and patent infringement related to aligner material, treatment planning, and intraoral scanner technologies. Defendants filed a motion to dismiss.
• Straumann Litigation: Defendants filed counterclaims on July 9, 2024 (amended August 29, 2025) alleging antitrust violations, false advertising, unfair competition, breach of contract, and fraud in procuring patents. Align filed a motion to dismiss counterclaims.
• Straumann Litigation: The PTAB denied institution of two of Defendants' eight IPR petitions on October 23, 2025, and instituted proceedings on one IPR on the same date. Decisions on the remaining five IPRs are expected by November 8, 2025.
• Angelalign Technology, Inc. Actions: Align initiated two actions in the European Union Patent Court on August 15, 2025, for patent infringement related to use interface and attachments. Defendants responded to one action on October 23, 2025.
• Angelalign Technology, Inc. Actions: Align filed a lawsuit in the U.S. District Court for the Eastern District of Texas on August 18, 2025, alleging patent infringement related to multilayer materials, bite ramps, and power ridges.
• Angelalign Technology, Inc. Actions: Align initiated two actions in the China Intermediate Peoples Court on August 18, 2025, and another on September 10, 2025, for patent infringement related to attachments, force-based treatment planning, and extraction site closure.
• Angelalign Technology, Inc. Actions: Align filed a complaint at the U.S. International Trade Commission (ITC) on September 23, 2025, alleging unlawful importation and sale of infringing clear aligners, seeking exclusion and cease-and-desist orders. The ITC has not yet instituted this investigation due to a government shutdown.
• Angelalign Technology, Inc. Actions: Angelalign filed a legal action against Align in the Beijing Intellectual Property Court on August 22, 2025, alleging patent violation related to undercut detection for mold manufacturing and seeking damages/injunctive relief.
• The company is involved in various other claims, suits, investigations, and proceedings in the ordinary course of business, but currently does not believe these matters, individually or in the aggregate, will materially affect its financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: Significant decrease in net income and EPS, along with lower margins, could negatively impact shareholder returns and stock price. The ongoing share repurchase program aims to return capital, but its effectiveness is subject to market conditions.
• Employees: The 2025 restructuring plan involves a reduction in the global workforce, leading to involuntary termination benefits and potential job losses. The return-to-office policy (effective September 1, 2025) may impact employee morale and retention, especially in a competitive talent market.
• Customers (Dental Professionals): Macroeconomic conditions and a shift towards traditional treatments may reduce demand for Align's clear aligners and iTero scanners. Lower ASPs and increased competition could offer more choices or lower prices, but also indicate market pressure. Legal disputes with competitors like Straumann and Angelalign could affect product availability or market perception.
• Suppliers: Dependence on sole or limited suppliers for key components and materials exposes the supply chain to risks, potentially impacting product availability and costs.
• Creditors: The company maintains a strong cash position and no outstanding borrowings on its credit facility, indicating good liquidity and low immediate risk for creditors.
• Regulatory Authorities: Ongoing legal proceedings (antitrust, patent infringement) and compliance with evolving regulations (privacy, AI, sustainability) require significant attention and resources, potentially leading to fines or restrictions if not managed effectively.

Next Steps

• Complete the disposition of specifically identified manufacturing assets by December 31, 2025.
• Complete the 2025 Restructuring plan, which will continue through the fourth quarter of 2025.
• Attend the Final Approval/Fairness hearing for the Section 1 antitrust settlement on November 20, 2025.
• Await decisions on the remaining five IPRs in the Straumann Litigation by November 8, 2025.
• Attend the Upper Tribunal hearing for the HMRC VAT matter scheduled for May 2026.
• Continue to evaluate the effect of ASU 2025-06 (Internal-Use Software) on annual consolidated financial statements.
• Adopt ASU 2023-09 (Improvements to Income Tax Disclosures) for fiscal years beginning after December 15, 2024.
• Evaluate the effect of ASU 2024-03 (Expense Disaggregation Disclosures) on consolidated financial statement disclosures.
• Repurchase an additional $128.4 million of common stock under the April 2025 Repurchase Program during the fourth quarter of 2025 and through January 2026.
• Monitor the enactment of legislation to evaluate the impact of changing global tax laws.

Key Dates

Recommendation

Align Technology's Q3 2025 results show a significant decline in net income and EPS, primarily due to substantial restructuring charges, asset impairments, and a notable increase in the effective tax rate. While the company demonstrated resilience with a slight revenue increase and growth in clear aligner case volumes, the average selling price per case declined, reflecting competitive pressures and a shift in product mix. The ongoing macroeconomic headwinds, including inflation and a shift towards traditional orthodontic treatments, present persistent challenges. The company is actively managing costs through restructuring and engaging in share repurchases, which are positive signals for capital allocation. However, the numerous and complex legal proceedings, coupled with the evolving regulatory landscape for AI and sustainability, introduce considerable uncertainty. Given the mixed financial performance, the proactive cost management, but also the significant operational and legal risks, a 'hold' recommendation is appropriate. Investors should monitor the effectiveness of the restructuring, the outcomes of key litigations, and the company's ability to navigate macroeconomic pressures and competitive dynamics to justify a more aggressive stance.

Keywords

Align Technology, ALGN, 10-Q, Quarterly Report, Invisalign, Clear Aligners, iTero, Intraoral Scanners, CAD/CAM, Dental Technology, Orthodontics, Financial Results, Earnings, Restructuring, Legal Proceedings, Antitrust, Patent Infringement, Share Repurchase, Capital Expenditures, Macroeconomic Risks, Geopolitical Risks, Supply Chain, Cybersecurity, ESG, AI, Taxation